324 related articles for article (PubMed ID: 30246299)
1. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
[TBL] [Abstract][Full Text] [Related]
2. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
3. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
[TBL] [Abstract][Full Text] [Related]
4. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
Tausche AK; Alten R; Dalbeth N; Kopicko J; Fung M; Adler S; Bhakta N; Storgard C; Baumgartner S; Saag K
Rheumatology (Oxford); 2017 Dec; 56(12):2170-2178. PubMed ID: 29029210
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2019 Jul; 57(7):345-352. PubMed ID: 30990408
[TBL] [Abstract][Full Text] [Related]
6. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Aksenov S; Peck CC; Eriksson UG; Stanski DR
Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29488355
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
Dalbeth N; Jones G; Terkeltaub R; Khanna D; Fung M; Baumgartner S; Perez-Ruiz F
Arthritis Res Ther; 2019 Jan; 21(1):8. PubMed ID: 30616614
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
[TBL] [Abstract][Full Text] [Related]
10. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
Saag KG; Fitz-Patrick D; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; Becker MA
Arthritis Rheumatol; 2017 Jan; 69(1):203-212. PubMed ID: 27564409
[TBL] [Abstract][Full Text] [Related]
11. Lesinurad: A Novel Agent for Management of Chronic Gout.
Haber SL; Fente G; Fenton SN; Walker EP; Weaver BM; Cano AJ; Vu K
Ann Pharmacother; 2018 Jul; 52(7):690-696. PubMed ID: 29482353
[TBL] [Abstract][Full Text] [Related]
12. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Terkeltaub R; Saag KG; Goldfarb DS; Baumgartner S; Schechter BM; Valiyil R; Jalal D; Pillinger M; White WB
Rheumatology (Oxford); 2019 Jan; 58(1):61-69. PubMed ID: 30124941
[TBL] [Abstract][Full Text] [Related]
13. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
[TBL] [Abstract][Full Text] [Related]
15. Lesinurad: First Global Approval.
Hoy SM
Drugs; 2016 Mar; 76(4):509-16. PubMed ID: 26861027
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout.
Pérez-Ruiz F; Jansen T; Tausche AK; Juárez-Campo M; Gurunath RK; Richette P
Drugs Context; 2019; 8():212581. PubMed ID: 31191704
[TBL] [Abstract][Full Text] [Related]
17. Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout.
Huneycutt E; Board C; Clements JN
J Pharm Pract; 2017 Jan; ():897190017734427. PubMed ID: 28980503
[TBL] [Abstract][Full Text] [Related]
18. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
Presa M; Pérez-Ruiz F; Oyagüez I
Clin Rheumatol; 2019 Dec; 38(12):3521-3528. PubMed ID: 31420811
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
Lin YJ; Lin SY; Lin CH; Wang ST; Chang SS
Clin Rheumatol; 2020 May; 39(5):1633-1648. PubMed ID: 31965378
[TBL] [Abstract][Full Text] [Related]
20. New urate-lowing therapies.
Abhishek A
Curr Opin Rheumatol; 2018 Mar; 30(2):177-182. PubMed ID: 29251661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]